New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
09:17 EDTOREXOrexigen looking for FDA approval in next few months, says Cowen
Cowen noted Orexigen announced Q4 results last night and provided an update on its regulatory processes. The firm remains positive on Contrave's potential lifecycle management opportunities and reiterates its Outperform rating and $10 price target.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 21, 2015
14:02 EDTOREXParagraph IV patent challenges submitted to FDA for Orexigen's Contrave
An Abbreviated New Drug Application, or ANDA, has been received by the Office of Generic Drugs containing a "Paragraph IV" patent certification for Contrave, the weight loss drug whose patent is owned by Orexigen Therapeutics, according to an FDA notice. The date on which the first substantially complete generic drug application was submitted to the Agency for Contrave was March 12, according to the posting. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use